October 12, 2012
Dave Hinds is a Principal Scientist in Statistical Genetics. 23andMe is passionate about research on a group of rare blood disorders called myeloproliferative neoplasms, or MPNs. Physicians who study these disorders consider them to be blood cancers, though individual prognoses can vary widely — some [...]
September 4, 2012
Dr. Ross Levine Last year 23andMe launched a Myeloproliferative Neoplasms Research Initiative to study this group of rare blood cancers. We are now very close to reaching our goal of enrolling 1,000 patients and are encouraged by what we’ve already learned. We’re also humbled that another star in the [...]
